Is IKT or ANRO more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Alto Neuroscience N/A -46.46% -39.09%

Does the media refer more to IKT or ANRO?

In the previous week, Alto Neuroscience had 8 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 9 mentions for Alto Neuroscience and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.37 beat Alto Neuroscience's score of 0.30 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alto Neuroscience 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IKT or PCRX?

In the previous week, Pacira BioSciences had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for Pacira BioSciences and 1 mentions for Inhibikase Therapeutics. Pacira BioSciences' average media sentiment score of 0.65 beat Inhibikase Therapeutics' score of 0.37 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HELP or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Cybin N/A -71.78% -64.81% Inhibikase Therapeutics N/A -42.80% -40.58%

Does the media prefer HELP or IKT?

In the previous week, Cybin had 8 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 9 mentions for Cybin and 1 mentions for Inhibikase Therapeutics. Cybin's average media sentiment score of 1.04 beat Inhibikase Therapeutics' score of 0.37 indicating that Cybin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SGP or IKT more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A -62.40% -24.83% Inhibikase Therapeutics N/A -42.80% -40.58%

Does the media favor SGP or IKT?

In the previous week, Spyglass Pharma had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Spyglass Pharma and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.37 beat Spyglass Pharma's score of 0.18 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Inhibikase Therapeutics (IKT) Competitors

$2.00 0.00 (0.00%)

Closing price 10/5/2026 04:00 PM Eastern

Extended Trading

$2.00 +0.00 (+0.25%)

As of 10/5/2026 07:30 PM Eastern

Compare

IKT vs. AMPH, ANRO, PCRX, HELP, and SGP

Should you buy Inhibikase Therapeutics stock or one of its competitors? Inhibikase Therapeutics's main competitors and comparable companies include Amphastar Pharmaceuticals (AMPH), Alto Neuroscience (ANRO), Pacira BioSciences (PCRX), Cybin (HELP), and Spyglass Pharma (SGP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inhibikase Therapeutics compare to Amphastar Pharmaceuticals?

Inhibikase Therapeutics (NASDAQ:IKT) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Inhibikase Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

In the previous week, Amphastar Pharmaceuticals had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Amphastar Pharmaceuticals and 1 mentions for Inhibikase Therapeutics. Amphastar Pharmaceuticals' average media sentiment score of 0.56 beat Inhibikase Therapeutics' score of 0.37 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibikase Therapeutics presently has a consensus target price of $5.40, suggesting a potential upside of 170.00%. Amphastar Pharmaceuticals has a consensus target price of $22.50, suggesting a potential downside of 11.31%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Amphastar Pharmaceuticals	2 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Amphastar Pharmaceuticals has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A
Amphastar Pharmaceuticals	$730.02M	1.48	$98.09M	$1.69	15.01

Amphastar Pharmaceuticals has a net margin of 10.76% compared to Inhibikase Therapeutics' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 14.98% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Amphastar Pharmaceuticals	10.76%	14.98%	6.96%

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Amphastar Pharmaceuticals beats Inhibikase Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Inhibikase Therapeutics (NASDAQ:IKT) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Inhibikase Therapeutics currently has a consensus target price of $5.40, indicating a potential upside of 170.00%. Alto Neuroscience has a consensus target price of $37.25, indicating a potential upside of 55.38%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Inhibikase Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Alto Neuroscience	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Inhibikase Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Alto Neuroscience had 8 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 9 mentions for Alto Neuroscience and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.37 beat Alto Neuroscience's score of 0.30 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alto Neuroscience	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inhibikase Therapeutics' return on equity of -42.80% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Alto Neuroscience	N/A	-46.46%	-39.09%

Inhibikase Therapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

Inhibikase Therapeutics beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Pacira BioSciences?

Inhibikase Therapeutics (NASDAQ:IKT) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pacira BioSciences has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A
Pacira BioSciences	$746.16M	1.34	$7.03M	$0.35	71.57

In the previous week, Pacira BioSciences had 1 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 2 mentions for Pacira BioSciences and 1 mentions for Inhibikase Therapeutics. Pacira BioSciences' average media sentiment score of 0.65 beat Inhibikase Therapeutics' score of 0.37 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pacira BioSciences has a net margin of 1.96% compared to Inhibikase Therapeutics' net margin of 0.00%. Pacira BioSciences' return on equity of 9.68% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Pacira BioSciences	1.96%	9.68%	5.30%

Inhibikase Therapeutics currently has a consensus price target of $5.40, suggesting a potential upside of 170.00%. Pacira BioSciences has a consensus price target of $30.14, suggesting a potential upside of 20.33%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Pacira BioSciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

Inhibikase Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Summary

Pacira BioSciences beats Inhibikase Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Cybin?

Cybin (NASDAQ:HELP) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Cybin currently has a consensus price target of $46.33, indicating a potential upside of 305.72%. Inhibikase Therapeutics has a consensus price target of $5.40, indicating a potential upside of 170.00%. Given Cybin's higher possible upside, analysts clearly believe Cybin is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Inhibikase Therapeutics has higher revenue and earnings than Cybin. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A

In the previous week, Cybin had 8 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 9 mentions for Cybin and 1 mentions for Inhibikase Therapeutics. Cybin's average media sentiment score of 1.04 beat Inhibikase Therapeutics' score of 0.37 indicating that Cybin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

17.9% of Cybin shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by insiders. Comparatively, 7.1% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inhibikase Therapeutics' return on equity of -42.80% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Cybin has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Summary

Cybin and Inhibikase Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

In the previous week, Spyglass Pharma had 5 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 6 mentions for Spyglass Pharma and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.37 beat Spyglass Pharma's score of 0.18 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spyglass Pharma has higher earnings, but lower revenue than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A
Inhibikase Therapeutics	$260K	1,073.38	-$48.26M	-$0.43	N/A

Inhibikase Therapeutics' return on equity of -42.80% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	-62.40%	-24.83%
Inhibikase Therapeutics	N/A	-42.80%	-40.58%

Spyglass Pharma presently has a consensus target price of $44.00, indicating a potential upside of 71.94%. Inhibikase Therapeutics has a consensus target price of $5.40, indicating a potential upside of 170.00%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Inhibikase Therapeutics beats Spyglass Pharma on 9 of the 14 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$279.07M	$12.23B	$7.14B	$13.26B
Dividend Yield	N/A	2.65%	2.53%	17.36%
P/E Ratio	-4.65	799.72	274.34	26.20
Price / Sales	1,073.38	791.07	629.40	95.18
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	0.87	10.68	11.23	6.40
Net Income	-$48.26M	$2.83B	$3.49B	$381.07M
7 Day Performance	-0.99%	-2.01%	-1.31%	-0.28%
1 Month Performance	-20.00%	-6.55%	-5.97%	-4.51%
1 Year Performance	23.46%	-4.70%	7.26%	1.63%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	2.1059 of 5 stars	$2.00 flat	$5.40 +170.0%	+20.5%	$279.07M	$260K	N/A	35	News Coverage
AMPH Amphastar Pharmaceuticals	2.0052 of 5 stars	$27.39 +4.8%	$22.50 -17.9%	-5.2%	$1.11B	$719.89M	16.21	1,976	Analyst Upgrade
ANRO Alto Neuroscience	2.3192 of 5 stars	$26.67 +0.7%	$37.25 +39.7%	+248.9%	$1.04B	N/A	N/A	68
PCRX Pacira BioSciences	3.4833 of 5 stars	$25.39 +1.1%	$30.14 +18.7%	+0.8%	$1.00B	$726.41M	72.54	829
HELP Cybin	4.4695 of 5 stars	$12.59 -0.2%	$46.33 +268.0%	N/A	$993.42M	N/A	N/A	100	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. AMPH, ANRO, PCRX, HELP, and SGP

How does Inhibikase Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Summary

How does Inhibikase Therapeutics compare to Pacira BioSciences?

Summary

How does Inhibikase Therapeutics compare to Cybin?

Summary

How does Inhibikase Therapeutics compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. AMPH, ANRO, PCRX, HELP, and SGP

How does Inhibikase Therapeutics compare to Amphastar Pharmaceuticals?

Which has more risk & volatility, IKT or AMPH?

Does the media favor IKT or AMPH?

Do analysts recommend IKT or AMPH?

Which has preferable earnings and valuation, IKT or AMPH?

Is IKT or AMPH more profitable?

Do institutionals & insiders hold more shares of IKT or AMPH?

Summary

How does Inhibikase Therapeutics compare to Alto Neuroscience?

Do analysts prefer IKT or ANRO?

Which has more risk & volatility, IKT or ANRO?

Do insiders and institutionals hold more shares of IKT or ANRO?

Does the media refer more to IKT or ANRO?

Is IKT or ANRO more profitable?

Which has higher valuation and earnings, IKT or ANRO?

Summary

How does Inhibikase Therapeutics compare to Pacira BioSciences?

Do insiders & institutionals hold more shares of IKT or PCRX?

Which has better valuation and earnings, IKT or PCRX?

Does the media favor IKT or PCRX?

Is IKT or PCRX more profitable?

Do analysts rate IKT or PCRX?

Which has more risk and volatility, IKT or PCRX?

Summary

How does Inhibikase Therapeutics compare to Cybin?

Do analysts recommend HELP or IKT?

Which has higher earnings & valuation, HELP or IKT?

Does the media prefer HELP or IKT?

Do institutionals & insiders believe in HELP or IKT?

Is HELP or IKT more profitable?

Which has more risk and volatility, HELP or IKT?

Summary

How does Inhibikase Therapeutics compare to Spyglass Pharma?

Does the media favor SGP or IKT?

Do insiders and institutionals hold more shares of SGP or IKT?

Which has higher earnings and valuation, SGP or IKT?

Is SGP or IKT more profitable?

Do analysts prefer SGP or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools